AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra (benralizumab) has been given authorisation as an add-on treatment for severe asthma sufferers, while Lynparza (olaparib) has been given the go-ahead as a maintenance therapy in patients with ovarian cancer who responded to chemotherapy, regardless of BRCA mutation status.
Original Article: AstraZeneca scores double approvals in Japan for asthma and ovarian cancer
NEXT ARTICLE